News
ICLR
309.44
+0.98%
2.99
ICLR Stock Earnings: Icon Beats EPS, Meets Revenue for Q1 2024
Icon reported results for the first quarter of 2024. Icon reported earnings per share of $3.47. The company reported revenue of $2.09 billion. Icon's revenue was above the analyst estimate for revenue of  $2.08 billion.
Investorplace · 11h ago
ICON adjusts 2024 revenue, EPS guidance ranges
Clinical research organization ICON Plc has adjusted its 2024 outlook ranges for revenue and adjusted EPS. Revenue for the year is now seen as $8.48B-$8.72B. In Q1 2024, ICON missed on the bottom line though revenue came in-line.
Seeking Alpha · 14h ago
Icon PLC: Q1 Earnings Snapshot
Barchart · 20h ago
Icon Q1 2024 Earnings Preview
Icon (NASDAQ:ICLR) is scheduled to announce Q1 earnings results on Wednesday, April 24th, after market close. The consensus EPS Estimate is $3.41 and the consensus revenue estimate is $2.09B. Over the last 2 years, ICLR has beaten EPS estimates 100% of the time.
Seeking Alpha · 1d ago
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
NASDAQ · 1d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Weekly Report: what happened at ICLR last week (0415-0419)?
Weekly Report · 3d ago
What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
ICON Public Limited Company (NASDAQ:ICLR) saw a share price growth of 16% on the NASDAQGS over the last few months. The stock is currently trading at US$288 on the share market. ICON is expected to grow its earnings over the next few years by 91%. The company is currently undervalued and could be a great opportunity to buy the stock. We look at the most recent data on ICON's outlook and valuation to see if the opportunity still exists.
Simply Wall St · 4d ago
Look Under The Hood: IWS Has 13% Upside
NASDAQ · 6d ago
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
NASDAQ · 6d ago
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
NASDAQ · 6d ago
Weekly Report: what happened at ICLR last week (0408-0412)?
Weekly Report · 04/15 09:18
ICLR Factor-Based Stock Analysis
NASDAQ · 04/10 18:04
Barclays Remains a Buy on Icon (ICLR)
TipRanks · 04/10 06:48
Weekly Report: what happened at ICLR last week (0401-0405)?
Weekly Report · 04/08 09:19
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neurocrine (NBIX)
TipRanks · 04/08 08:31
Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Icon (ICLR) and Teladoc (TDOC)
TipRanks · 04/05 12:41
ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Using the 2 Stage Free Cash Flow to Equity, ICON fair value estimate is US$415. ICON is estimated to be 25% undervalued based on current share price of US$313. Analyst price target for ICLR is 15% below our fair value estimates. We use the discounted cash flow model to estimate the company's intrinsic value.
Simply Wall St · 04/05 11:33
Icon Is Maintained at Outperform by Baird
Dow Jones · 04/04 17:24
Icon Price Target Raised to $362.00/Share From $345.00 by Baird
Dow Jones · 04/04 17:24
More
Webull provides a variety of real-time ICLR stock news. You can receive the latest news about ICON PLC through multiple platforms. This information may help you make smarter investment decisions.
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.